A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot (ACROBAT Evolve)
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Paltusotine (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms ACROBAT EVOLVE
- Sponsors Crinetics Pharmaceuticals
- 02 Nov 2020 Status changed from active, no longer recruiting to completed.
- 26 Oct 2020 According to a Crinetics Pharmaceuticals media release, the company is looking forward to meeting with the FDA to share these results and finalize the protocol for the planned Phase 3 program.
- 26 Oct 2020 According to a Crinetics Pharmaceuticals media release, the company will hold a a conference call at 8:00 a.m. Eastern Time today to discuss these results. In addition, a Key Opinion Leader (KOL) call will be held on November 20th to discuss these results in the context of the current standard of care with clinical experts.